EMA Checklist for annual updates for parallel distribution - Draft Guidance

June 23, 2022

22/06/2022
EMA/405782/2020 Rev. 3
Human Medicines Division

The European Medicines Agency (hereinafter 'the Agency') asks its applicants to use this checklist in advance of submission of an annual update for parallel distribution. You should be able to answer “Yes” to every item listed below unless a specific point is not applicable (“n/a”) to the application in question. In order to improve the quality of submissions, it is recommended to include the checklist with your submission.

Points 6 – 12 refer to the creation of scopes of change within an annual update. In case you are only updating the package leaflet and labelling and are not creating any additional scopes of change, please refer to points 1 – 5 only.

Upon receipt of an annual update for parallel distribution, the procedure manager proceeds to validate the documentation submitted in accordance with the checklist included below.

Updates to the information included in the IRIS form after submission of any notification for parallel distribution are only possible in exceptional cases, so the applicants should review the information included in the form carefully before submitting. Changes impacting fees would not be possible after submission. Only changes requested by the assessor would be possible and only by exception when properly justified.

Reference documents for further information

  • Parallel distribution regulatory and procedural guidance:

https://www.ema.europa.eu/en/human-regulatory/post-authorisation/parallel-distribution/

  • Frequently asked questions (FAQs) about parallel distribution:

https://www.ema.europa.eu/en/human-regulatory/post-authorisation/parallel-distribution/frequently-asked-questions-about-parallel-distribution

  • Public register of parallel distribution notices:

https://iris.ema.europa.eu/registerpd/

Download Checklist

Interested in learning more? Contact us today to find out how we can help with your global regulatory needs.




EMA Europe

June 23, 2022

EMA and the EUnetHTA 21 consortium set priorities for their collaboration Share

April 12, 2022 The European Medicines Agency (EMA) and the European Network for Health Technology Assessment (EUnetHTA) 21 consortium have published a PDF icon joint work plan until 2023. The focus...

Read More
EMA Europe

June 23, 2022

EMA Procedural guidance for variant strain(s) update to vaccines intended for protection against Human coronavirus

8 June 2022 EMA/175959/2021 Rev.2 Human Medicines Division Regulatory and procedural requirements Introduction In order to ensure the continued effectiveness of authorised COVID-19 vaccines, it may...

Read More
EMA EU

June 23, 2022

Products Management Services - Implementation of International Organization for Standardization (ISO) standards for the identification of medicinal products (IDMP) in Europe Introduction - EU Implemen

The Europe Introduction - EU Implementation Guide has been prepared by the European Medicines Agency (EMA) upon consultation with different stakeholders (representatives of marketing authorisation...

Read More